Castle Biosciences, Inc.
CSTL Healthcare Diagnostics & Research
Castle Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $344.2 million, up 3.66% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS fell 143.8%, free cash flow fell 43.3% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow CSTL
Castle Biosciences, Inc. (CSTL) EV/Sales
As of 16 October 2026, Castle Biosciences, Inc. (CSTL) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 0.5× (August 2025) to 23.2× (February 2021); the current reading is higher than 41% of that period. That is below the Diagnostics & Research industry median of 5.5× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 2.4× | 76.82% |
| FY2024 | 1.4× | (15.90%) |
| FY2023 | 1.6× | (35.54%) |
| FY2022 | 2.5× | (68.38%) |
| FY2021 | 8.0× | (43.03%) |
| FY2020 | 14.1× | 230.57% |
| FY2019 | 4.3× | 117.34% |
| FY2018 | 2.0× | 0.00% |
| FY2017 | 2.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.3× | (7.60%) |
| Mar 2026 | 1.4× | (41.73%) |
| Dec 2025 | 2.4× | 116.33% |
| Sep 2025 | 1.1× | 19.99% |
| 28 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MYGN Myriad Genetics, Inc. compare | 0.5× |
| FLGT Fulgent Genetics, Inc. compare | 1.0× |
| CSTL Castle Biosciences, Inc. | 2.0× |
| OPK OPKO Health, Inc. compare | 2.0× |
| NEO NeoGenomics, Inc. compare | 3.4× |
| WGS GeneDx Holdings Corp. compare | 4.1× |
| VCYT Veracyte, Inc. compare | 5.3× |
| CDNA CareDx, Inc. compare | 6.4× |
| PSNL Personalis, Inc. compare | 20.9× |
| Diagnostics & Research industry median | 5.5× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)